Big Pharma's Battle: Sanofi Drops $750 Million Maze Deal Amidst FTC Antitrust Lawsuit

The pharmaceutical industry is facing a three-front battle with the Federal Trade Commission (FTC), Medicare, and the White House. The FTC is scrutinizing drug company deals to slow down growing monopolies in the pharma business. The White House is considering licensing drugs developed with federal funding to reduce costs, which has raised concerns about intellectual property rights. Medicare is targeting 10 drugs for price negotiations, leading to lawsuits from pharmaceutical companies. Experts believe that while these actions may send a message to the industry, the long-term odds of success are not great, and the legal system may ultimately decide the outcome.